«A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF THE ORAL DNA POLYMERASE THETA INHIBITOR (POLQI) GSK4524101 AND THE PARP INHIBITOR (PARPI) NIRAPARIB IN ADULT PARTICIPANTS WITH SOLID TUMORS»